retatrutide phase 3 triumph The numbers from Lilly's trial dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user Lilly's triple agonist delivers up

( GLP-1 RAs recently appearing on the market, in particular liraglutide, semaglutide and tirzepatide (a GIP/GLP-1 RA dual agonist) seek to overcome the problem of the short plasma half-life of native GLP-1 through (i) changing the amino acid sequence of the peptide so that it is no longer broken down by DPP-4, and/or (ii) attaching a long acyl chain to the peptide, thus allowing it to bind to albumin, and avoid rapid elimination via the kidney

2022;185:2478-94 e28

USD 39.95 Prices may be subject to local taxes which are calculated during checkout References Buse, J

A $200 contribution lowers that range further, from $2 PMPM to $10 PMPM